Proving an incrementally better product enhances value can be expensive (because it takes many patients to demonstrate a small difference in an active comparator trial), and of course, risky as well.

FORBES: Strategy: Why Big Pharmas Do What They Do -- And How Silicon Valley Might Help Them Think Differently